• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens
【2h】

Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens

机译：IL-2治疗无症状的HIV感染者对有丝分裂原，召回抗原和HIV相关抗原的增殖反应的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The effects of IL-2 therapy on lymphoproliferative responses to mitogens, recall antigens and HIV epitopes were studied in asymptomatic HIV-infected patients enrolled in a phase II study of intermittent continuous intravenous (CIV) IL-2 and subcutaneous infusions of polyethylene glycol-modified (PEG) IL-2. Sixteen consecutive patients randomized to receive CIV IL-2 (n = 5), PEG IL-2 (n = 7) or anti-viral therapy alone (n = 4) were studied. All patients were vaccinated with tetanus toxoid (TT) before receiving therapy. Proliferative responses to phytohaemagglutinin (PHA), soluble anti-CD3, TT, streptokinase/streptodornase (SK/SD) and 11 previously described HIV-specific T-helper epitopes from gag and env were studied at weeks 0, 16, 30 and 48. Median CD4+ lymphocyte increases of 272 and 255 CD4+ cells/μl were observed in the CIV IL-2 and PEG IL-2 groups at week 48, while decreasing by 104 cells/μl in the anti-retroviral therapy alone group. At each time point proliferative responses to PHA, anti-CD3, TT and SK/SD were not different between treatment arms. Similarly, no differences in responses to HIV epitopes were found between the groups and no new responses to HIV epitopes were detected. IL-2 therapy results in a significant increase in peripheral blood CD4+ lymphocyte count, but this increase is not associated with quantifiable improvements in lymphoproliferative responses to mitogens, recall or HIV antigens.
机译：在无症状HIV感染的患者中进行了IL-2治疗对促分裂原对促分裂素，回忆抗原和HIV表位的淋巴增生反应的影响，该患者参加了间歇性连续静脉（CIV）IL-2和经聚乙二醇修饰的皮下输注的II期研究（PEG）IL-2。研究了16名连续随机接受CIV IL-2（n = 5），PEG IL-2（n = 7）或单独抗病毒治疗（n = 4）的患者。所有患者在接受治疗前均接种破伤风类毒素（TT）。在第0、16、30和48周时研究了对植物血凝素（PHA），可溶性抗CD3，TT，链激酶/链脲酶（SK / SD）和11种先前描述的来自gag和env的HIV特异性T-辅助表位的增殖反应。在第48周时，在CIV IL-2和PEG IL-2组中，CD4 +淋巴细胞的中位数增加了272和255 CD4 +细胞/μl，而在单独的抗逆转录病毒疗法组中，CD4 +淋巴细胞减少了104细胞/μl。在每个时间点，治疗组之间对PHA，抗CD3，TT和SK / SD的增殖反应均无差异。同样，各组之间对HIV表位的反应没有差异，也没有检测到对HIV表位的新反应。 IL-2治疗导致外周血CD4 +淋巴细胞计数显着增加，但这种增加与对促细胞分裂素，召回或HIV抗原的淋巴增生反应的可量化改善无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号